[1]饶少锋 江波涛 杨岳利 陆凡 殷平平 陈成.肿瘤治疗前临床TNM分期评估的影响因素分析[J].中国卫生质量管理,2025,32(01):043-46.[doi:10.13912/j.cnki.chqm.2025.32.1.10]
 RAO Shaofeng,JIANG Botao,YANG Yueli.Analysis of Influencing Factors in Clinical TNM Staging Evaluation before Treatment of Tumor[J].Chinese Health Quality Management,2025,32(01):043-46.[doi:10.13912/j.cnki.chqm.2025.32.1.10]
点击复制

肿瘤治疗前临床TNM分期评估的影响因素分析()
分享到:

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第32卷
期数:
2025年01期
页码:
043-46
栏目:
医疗质量
出版日期:
2025-01-15

文章信息/Info

Title:
Analysis of Influencing Factors in Clinical TNM Staging Evaluation before Treatment of Tumor
作者:
饶少锋 江波涛 杨岳利 陆凡 殷平平 陈成
咸宁市中心医院/湖北科技学院附属第一医院
Author(s):
RAO Shaofeng JIANG Botao YANG Yueli
Xianning Central Hospital/The First Affiliated Hospital of Hubei University of Science and Technology
关键词:
肿瘤临床TNM分期评估率医疗质量
Keywords:
TumorClinical TNM StagingEvaluation RateMedical Quality
分类号:
R197.3;R73
DOI:
10.13912/j.cnki.chqm.2025.32.1.10
文献标志码:
A
摘要:
目的探讨肿瘤治疗前临床TNM分期评估影响因素,为提高肿瘤治疗前临床TNM分期评估率提供参考方法。方法回顾性分析某院2023年1月1日-12月31日诊断为乳腺癌、胃癌、肝癌、肺癌及结直肠癌的1 499名肿瘤患者病历资料,采用描述性分析、秩和检验、卡方检验、二元Logistic回归分析等进行数据统计分析。结果该院肿瘤治疗前临床TNM分期评估率为61.24%。不同肿瘤病种治疗前临床TNM分期评估率差异有统计学意义(P<0.05)。质控、培训、肿瘤病种、主管医生性别、住院天数为肿瘤治疗前临床TNM分期评估的主要影响因素(P<0.05)。结论肿瘤治疗前临床TNM分期评估受多种因素影响。医院及科室需加强培训,并将肿瘤治疗前临床TNM分期评估纳入质控指标,缩短患者检查及手术操作时间,提升各科室诊疗水平,以提高肿瘤治疗前临床TNM分期评估率。
Abstract:
ObjectiveTo explore the influencing factors of clinical TNM staging evaluation before tumor treatment, and to provide reference methods for improving the evaluation rate of clinical TNM staging before tumor treatment.MethodsThe medical records of 1 499 patients with breast cancer, gastric cancer, liver cancer, lung cancer and colorectal cancer diagnosed in a hospital from January 1 to December 31,2023 were retrospectively analyzed. Descriptive analysis, rank sum test, chi-square test and binary logistic regression analysis were used for statistical analysis.ResultsThe evaluation rate of clinical TNM staging before tumor treatment in the hospital was 61.24 %. There was a statistically significant difference in the evaluation rate of clinical TNM staging before treatment in different tumor diseases (P<0.05). Quality control, training, tumor disease, gender of the doctor in charge, and length of hospital stay were the main influencing factors for clinical TNM staging evaluation before tumor treatment (P<0.05). Conclusion The evaluation of clinical TNM staging before tumor treatment is affected by many factors. Hospitals and departments need to strengthen training, and include clinical TNM staging evaluation before tumor treatment into quality control indicators, shorten patient examination and operation time, and improve the diagnosis and treatment level of each department, so as to improve the evaluation rate of clinical TNM staging before tumor treatment.

参考文献/References:

[1]国家卫生健康委办公厅.关于印发国家三级公立医院绩效考核操作手册(2024版)的通知:国卫办医政函〔2024〕87号[EB/OL].(2024-03-15)[2024-08-15].http://www.nhc.gov.cn/yzygj/s359 4q/202403/94a97921a9b043e8b8e3315aed9f 1627.shtml.[2]国家卫生健康委.关于印发《三级医院评审标准(2022年版)》及其实施细则的通知:国卫办医发〔2022〕31号[EB/OL].(2022-12-06)[2024-08-15].https://www.gov.cn/zhengce/zhengceku/2022-12/18/content_5732583.htm#:~:text.[3]林伟龙,杨谨成,杨 娟,等.我国肿瘤专业医疗质量管理与控制体系现状分析[J].中国医院管理,2023,43(2):57-59.[4]冯淑秀,蒋海彬,吴美娜,等.厦门市某院恶性肿瘤化疗患者住院分布情况及其病历质控结果比较[J].江苏卫生事业管理,2022,33(2):176-180.[5]NOONE AM,SCHUSSLER N,NEGOITA S,et al.Availability of TNM staging data elements in the medical record and training needs assessment:results from the 2014 SEER training needs assessment for TNM study[J].Journal of Registry Management,2015,42(2):40-47.[6]尹英杰,刘 玲,齐荣君.点对点专科专人培训法在提高住院病案首页质量中的应用[J].中国医疗管理科学,2023,13(1):72-76.[7]文裕慧,衡 驰,吴頔,等.肿瘤医院专科医师规范化培训制度建设与效果评估[J].医院管理论坛,2020,37(3):53-56.[8]邓 明,林伟龙,安 宇,等.关于肿瘤治疗前临床TNM分期评估的思考[J].中国卫生质量管理,2022,29(11):9-11.[9]国家卫生健康委办公厅.关于印发原发性肝癌诊疗指南(2022年版)的通知:国卫办医函〔2022〕12号[EB/OL].(2022-01-10)[2024-08-15].http://www.nhc.gov.cn/yzygj/s7659/202201/a01ceb75c62b4 86fa459e36ba0fdfdbc.shtml.[10]VOGEL A,MEYER T,SAPISOCHIN G,et al.Hepatocellular carcinoma[J].Lancet,2022,400(10360):1345-1362.[11]孙 琛.肿瘤多学科协作诊疗模式运行质量评价指标体系构建研究:以山东省D医院为例[D].济南:山东大学,2023.[12]LEE JH,MOHAMED T,RAMSEY C,et al.A hospital-wide intervention to improve compliance with TNM cancer staging documentation[J].Journal of the National Comprehensive Cancer Network,2021,20(4):351-360.[13]姚月宁,鲍 伟,董四平,等.基于适宜技术理论的双DRG绩效管理模式探究[J].中国卫生质量管理,2024,31(4):73-77.[14]刘 玲.DIP付费对降低同一病种医疗费用及医保控费管理的效果[J].中国卫生标准管理,2024,15(7):51-54.[15]周雅利.外科住院医师病历书写中诊断缺陷现状及影响因素分析[J].四川解剖学杂志,2019,27(2):150-152,156.[16]陈香兰,奉水东,刘 波,等.湖南省某三甲医院5 667份出院病案质量分析[J].中国病案,2023,24(12):34-37.[17]郭 超.某院15 440份终末病案质量分析[J].中国病案,2023,24(6):17-20.[18]AMIN MB,GREENE FL,EDGE SB,et al.The eighth edition AJCC cancer staging manual:continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J].CA:A Cancer Journal for Clinicians,2017,67(2):93-99.

相似文献/References:

[1]陈晓炜 邵玉婷 耿劲松 陈钱.肿瘤新兴技术水平扫描报告分析及启示[J].中国卫生质量管理,2018,25(06):099.[doi:10.13912/j.cnki.chqm.2018.25.6.29]
[2]林伟龙邓明梁锌甘蓝霞杨娟王惠杨谨成杨文静.2017年-2019年我国三级公立医院肿瘤住院患者医疗服务与质量安全分析[J].中国卫生质量管理,2022,29(11):001.[doi:10.13912/j.cnki.chqm.2022.29.11.01 ]
 LIN Weilong,DENG Ming,LIANG Xin.Analysis on Medical Service and Quality Safety of Tumor Inpatients in Chinese Tertiary Public Hospitals from 2017 to 2019[J].Chinese Health Quality Management,2022,29(01):001.[doi:10.13912/j.cnki.chqm.2022.29.11.01 ]
[3]邓明时黎明林伟龙杨谨成安宇杨娟周成诚杨文静.我国肿瘤单病种质控路径实践与展望[J].中国卫生质量管理,2022,29(11):006.[doi:10.13912/j.cnki.chqm.2022.29.11.02 ]
 DENG Ming,SHI Liming,LIN Weilong.Practice and Prospect of Quality Control Path of Single Disease of Tumor in China[J].Chinese Health Quality Management,2022,29(01):006.[doi:10.13912/j.cnki.chqm.2022.29.11.02 ]
[4]邓明林伟龙安宇杨娟杨文静.关于肿瘤治疗前临床TNM分期评估的思考[J].中国卫生质量管理,2022,29(11):009.[doi:10.13912/j.cnki.chqm.2022.29.11.03 ]
 DENG Ming,LIN Weilong,AN Yu.Consideration on Clinical TNM Stage Evaluation before Tumor Treatment[J].Chinese Health Quality Management,2022,29(01):009.[doi:10.13912/j.cnki.chqm.2022.29.11.03 ]
[5]林伟龙王惠杨文静.我国肿瘤专业医疗质量控制中心建设现状调查[J].中国卫生质量管理,2024,31(02):035.[doi:10.13912/j.cnki.chqm.2024.31.2.09]
 LIN Weilong,WANG Hui,YANG Wenjing.The Construction of Tumor Professional Medical Quality Control Center in China: a Cross-Sectional Study[J].Chinese Health Quality Management,2024,31(01):035.[doi:10.13912/j.cnki.chqm.2024.31.2.09]
[6]周成诚 杨娟 杨谨成 时黎明 安宇 王惠 郑苏菲 杨文静.我国肺癌多学科诊疗建设现状调查研究[J].中国卫生质量管理,2024,31(11):035.[doi:10.13912/j.cnki.chqm.2024.31.11.08]
 ZHOU Chengcheng,YANG Juan,Yang Jincheng.Investigation on the Current Situation of Multi-Disciplinary Treatment of Lung Cancer in China[J].Chinese Health Quality Management,2024,31(01):035.[doi:10.13912/j.cnki.chqm.2024.31.11.08]

更新日期/Last Update: 2025-01-15